Nasdaq Hrtx News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq hrtx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Hrtx Today - Breaking & Trending Today
Pekin Hardy Strauss Inc. lessened its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) by 38.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 36,470 shares of the biotechnology company’s stock after selling 22,625 shares during the period. Pekin Hardy Strauss Inc.’s holdings in Heron […] ....
Pekin Hardy Strauss Inc. lowered its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) by 38.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,470 shares of the biotechnology company’s stock after selling 22,625 shares during the quarter. […] ....
Capital One Financial started coverage on shares of Heron Therapeutics (NASDAQ:HRTX – Free Report) in a research report sent to investors on Tuesday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $6.00 price objective on the biotechnology company’s stock. Capital One Financial also issued estimates for Heron Therapeutics’ Q1 2024 earnings at […] ....
Capital One Financial started coverage on shares of Heron Therapeutics (NASDAQ:HRTX – Free Report) in a research note published on Tuesday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $6.00 target price on the biotechnology company’s stock. Capital One Financial also issued estimates for Heron Therapeutics’ Q1 2024 earnings at ($0.09) EPS, […] ....
Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) – Analysts at Capital One Financial issued their Q1 2024 earnings per share estimates for Heron Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Capital One Financial analyst T. Chiang expects that the biotechnology company will post earnings per share of ($0.09) […] ....